Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma

Leuk Lymphoma. 2019 Aug;60(8):2085-2087. doi: 10.1080/10428194.2018.1551537. Epub 2019 Jan 11.

Authors

Peter A Forsberg¹, Andrew Hammes², Diana Abbott², Daniel W Sherbenou¹, Adriana Rossi³, David Jayabalan³, Ruben Niesvizky³, Tomer M Mark¹, Scott Ely⁴

Affiliations

¹ a Division of Hematology , University of Colorado , Aurora , CO , USA.
² b University of Colorado, School of Public Health , Aurora , CO , USA.
³ c Division of Hematology and Oncology , Weill Cornell Medical College , New York , NY , USA.
⁴ d Translational Pathology/Translational Medicine , Bristol-Myers Squibb , Princeton , NJ , USA.

PMID: 30632821
DOI: 10.1080/10428194.2018.1551537

No abstract available

Publication types

Letter

MeSH terms

Biomarkers
Biopsy
Bone Marrow / pathology
Cell Proliferation
Disease Progression
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Multiple Myeloma / diagnosis*
Multiple Myeloma / etiology
Multiple Myeloma / metabolism
Prognosis
Recurrence

Substances

Biomarkers